跳至主要内容
临床试验/EUCTR2014-005472-29-IT
EUCTR2014-005472-29-IT进行中(未招募)1 期

Safety and efficay of 0.2% propranolol eye drops in newborns with retinopathy of prematurity: a pilot study - na

AZIENDA OSPEDALIERO-UNIVERSITARIA MEYER0 个研究点目标入组 96 人开始时间: 2020年11月4日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
96

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Newborns with gestational ages between 23 and 32 weeks affected by classic stage 1 ROP.
  • 2. Parents informed consent.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Newborns with:
  • 1. cardiac failure
  • 2. recurrent episodes of bradycardia (BPM < 90)
  • 3. atrioventricular block 2nd and/or 3rd degrees
  • 4. significant cardiovascular congenital anomalies (except of patent foramen ovale, patent ductus arteriosus o defects of the interventricular septum)
  • 5. hypotension
  • 6. serious renal failure
  • 7. cerebral bleeding (ongoing)
  • 8. other diseases for which the use of beta blockers is contraindicated
  • 9. ROP stage > 1

研究者

相似试验

Safety and efficay of 0.2% propranolol eye drops in... | 临床试验